Study of 209 Early RA (<1yr) pts found 23 (11%) with Drug Free Remission (DFR) after 74 mos of F/U; DFR maintained x 48 mo (18–82). DFR was assoc w/ early persistence on Therapy (HR 3.84). Adhering to prescribed treatment may lead to DFR https://t.co/WAX6RWhToU https://t.co/ChlbHDDKCZ

• https://bit.ly/3cc2Vop

Favorable Pregnancy Outcomes in Spondyloarthritis Pregnancy often occurs in women with axial spondyloarthritis (axSpA), and a recent cohort study suggests outcomes are generally better than what had been reported in the literature. https://t.co/piAjx1Ugsu https://t.co/N6SGYOM6F1

• https://bit.ly/3Ah1bCg

Cluster analysis of 649 #GPA patients (age 60 yrs) finds 3 clusters: 1)Limited dz w/ ENT + cough(n=426) - many evovle to gen dz @ yr 1 2) Generalised non-renal Dz (176) ) 3) Renal dominant Dz(47) Mortality in #1, signif lower than mortality in #2 & #3 https://t.co/XgZVt9b73n

• https://bit.ly/3pC63Nw

HIgher mortality in thos with lower serum uric acid levels, is partly explained by low SUA assoc w/ sarcopenia and weight loss. NHANES study (1999-2006) of 13,979 people shows low SUA assoc w/ low lean mass, underweight BMI, & weight loss https://t.co/YC2a6eXqCb https://t.co/aZ18jbCcn4

• https://bit.ly/3A8XtdY

Rituximab Efficacy in Systemic Sclerosis The DESIRES trial studied rituximab (RTX) in patients with systemic sclerosis (SSc) and showed clinically significant improvement in skin and lung outcomes after a subsequent 24-week open-label extension phase. https://t.co/8wWrt8GQ5v https://t.co/CIQKUyngN5

• https://bit.ly/3wdt5hm

Low Dose IL-2 Therapy in SLE A multicentre, proof-of-concept trial of suggests that low-dose IL-2 therapy may be effective in moderate-to-severe SLE. https://t.co/PNOp3Zdc8M https://t.co/B8DmUs5iuH

• https://bit.ly/3Cj4E5T

Gout T2T: Rheumatology societies target urate <5 mg/dl (0.30 mmol/l) or <6 mg/dl (<0.36 mmol/l) - below point of urate saturation -->MSU crystal dissolution. Achieving target reduces flares & tophi; but these clinical benefits take time. https://t.co/bR0vh01mvP https://t.co/JFJ1EWAhoF

• https://go.nature.com/3wliaCj

Drug-Induced Lupus from Proton Pump Inhibitors A wide range of therapies have been implicated in causing drug-induced lupus erythematosus (DIL); now it appears that proton pump inhibitors (PPIs) can be added to the list of causative drugs. https://t.co/72w2dp9tfc https://t.co/dALeVbzOwo

• https://bit.ly/3whi1A2

NEJM Clinical Images: 74-yoF with psoriatic arthritis has swelling of the fifth finger; found to have nontender, subcutaneous nodules in the hypothenar region and over the fifth finger. https://t.co/9fJ6Ci1rDm https://t.co/IkAKBtPRJ3

• https://bit.ly/3AcJ7cn

JUNIPERA Study - Secukinumab in Juvenile PsA & ERA JUNIPERA study evaluated SEC in children with ERA and JPsA and was found to be safe and effective in patients with active ERA and JPsA who previous failed to respond to conventional therapy. https://t.co/ncvG8ZIcdE

Are you a fan of the RheumNow podcast? Please rate, like and review us wherever you get your podcast. We'd appreciate it!

Urine-soluble CD163 as a biomarker in #SLE: usCD163 significantly higher w/ active lupus nephritis & correlates w/ UPCR, disease activity, anti-dsDNA Ab levels and a higher chronic kidney disease stage. https://t.co/gbSn0ZcFEK https://t.co/qjOSNvkIPC

• https://bit.ly/3KeZ86w

Managing JDM with Calcinosis Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow and discusses a case of refractory juvenile dermatomyositis with calcinosis. https://t.co/6tvK90Yngc https://t.co/hyXtOdP65H

• https://bit.ly/3QWe6Ap

Melatonin Use Growing, Inappropriate & Potentially Unsafe With nearly 1/3 of adults, adolescents and children having sleep difficulties, many resort to using melatonin. But is it effective, safe and warranted? https://t.co/JrvfN1Awy3 https://t.co/NbVKAuUT1u

• https://bit.ly/3AtTmur

Rituximab Efficacy in Systemic Sclerosis The DESIRES trial studied rituximab (RTX) in patients with systemic sclerosis (SSc) and showed clinically significant improvement in skin and lung outcomes after a subsequent 24-week open-label extension phase. https://t.co/0GvUYrBJLs https://t.co/rhhihBY03Z

• https://bit.ly/3psNNpA